Clinical Trial: Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07412613) titled 'Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer' on Feb. 09.

Brief Summary: This is a randomized, open-label, controlled, multicenter phase 3 study. All patients are resectable microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer. The purpose of this study is to evaluate the efficacy and safety of neoadjuvant/adjuvant treatment of AK104 (Cadonilimab) versus adjuvant chemotherapy in patients with resectable MSI-H/dMMR conlon cancer.

Study Start Date: March 15

Study Type: INTERVENTIONAL

Condition: Resectable Colon Cancer MSI-H/d...